×

Sign In

Search
Home

Lexicon to license obesity drug to Novo Nordisk in up to $1 billion deal

By Thomson Reuters Mar 28, 2025 | 6:41 AM

(Reuters) -Lexicon Pharmaceuticals said on Friday it has entered into an agreement with Novo Nordisk to license its non-incretin-based experimental obesity drug for up to $1 billion.

(Reporting by Sneha S K; Editing by Krishna Chandra Eluri)

Israeli foreign minister denies reports of Lebanon talks, interceptor shortages

US airline CEOs urge Congress to end standoff, pay airport security officers

Oscars' top prize up for grabs as unease hangs over Hollywood

Uganda opposition leader Bobi Wine says he has left country after disputed vote

Oil poised for further gains as Middle East conflict threatens export facilities

Zelenskiy says Ukraine wants money, technology in return for Middle East drone help

Privacy Policy
Terms Of Service

Copyright © 2026. All Rights Reserved.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

For the health and safety of everyone, our offices are temporarily closed to the public. If you have won a prize from us we will be mailing it to you or will contact you with specific information needed to redeem your prize. Feel free to call us with questions during weekday business hours at 715-842-1672.